Summary:
Click image to enlarge
A phase 3 randomized, double-blinded, placebo-controlled multicenter trial with open-lable extension to evaluate the efficacy, safety, and tolerability of efgartigimod PH20 subcutaneous adminstered by prefilled syringe in adult patients with primary Sjogren's disease.
Qualified Participants Must:
• Need to be at least 18 years age
•
Have been diagnosed with Sjogren's disease(study staff will go over in detail about the condition)
•
Capable to sign the informed consent
Qualified Participants May Receive:
Subjects will be compensated for their time and travel.